Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
08/23/2022 - 07:30 AM
BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022:
Citi’s 17th Annual Biopharma Conference September 7th -8th Boston, MA
Wells Fargo’s 2022 Healthcare Conference September 7th -9th Boston, MA
Portfolio managers and analysts who would like to request a meeting with management should contact their representative at the respective hosting firms.
About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com , and follow the company on Twitter @SenseiBio and LinkedIn .
Investor Contact: Michael Biega Senior Director, Investor Relations Sensei Biotherapeuticsmbiega@senseibio.com
Media Contact: Chris Railey Ten Bridge Communicationschris@tenbridgecommunications.com
Sensei Biotherapeutics Inc
SNSE Rankings
#4942 Ranked by Stock Gains
SNSE Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About SNSE
sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit